Addex Pharmaceuticals Ltd, the Swiss developer of small molecule therapeutic agents, said that Raymond Hill was elected to its board of directors at its annual general meeting on 18 April 2008.
Dr Hill is retiring at the end of April 2008 as head of licensing and external research at Merck Sharp & Dohme, the European arm of Merck & Co, Inc.
He will formally take his seat on Addex’s board on 1 May 2008.
Among other things, Dr Hill is visiting professor of neuroscience and mental health at the Imperial College London, visiting industrial professor of pharmacology at the University of Bristol, visiting professor and chairman of the external advisory board at the School of Biological and Health Sciences of the University of Surrey and visiting professor of physiology and pharmacology at the University of Strathclyde.
The AGM also rotated representatives from institutional investors on its board. Francesco De Rubertis, general partner of Index Ventures and Alexandra Goll, general partner of TVM Capital, stepped down at the end of their three-year terms. Meanwhile, Antoine Papiernik, managing partner of Sofinnova Partners and Deborah Harland, general partner of SR One, the investment arm of GlaxoSmithKline, were re-elected to the board for a three-year term.
Source
Addex press release, 18 April 2008
Copyright 2008 Evernow Publishing Ltd